Bioanalysis Expert, therapeutic oligonucleotides

Are you an expert in bioanalysis of oligonucleotides and mass spectrometry? Would you like to apply your expertise in a company that is accelerating innovative science and turn ideas into life changing medicines? Join us to discover future treatment of Cardiovascular, Renal and Metabolic diseases!
Working at AstraZeneca means being entrepreneurial, thinking big and working together to make the impossible a reality. We are committed to the development of next generation innovative medicines and are currently building a cross-functional oligonucleotide capability for the treatment of diseases across therapy areas.
As part of the oligonucleotide capability build expansion, we are now recruiting a Bioanalysis Expert to join the Drug, Metabolism and Pharmacokinetics (DMPK) department within Research and Early Development Cardiovascular, Renal and Metabolism (CVRM). The position is placed at AstraZeneca’s dynamic R&D site in Gothenburg, Sweden.
CVRM is one of the three main therapeutic research areas within AstraZeneca which deliver candidate drugs into clinical development. CVRM DMPK interacts with other functions in supporting CVRM projects along the value chain, from target selection all the way to launch and life cycle management. Are you the one to help us increase our capability regarding ADME and Bioanalysis of oligonucleotide therapeutics?
What you’ll do
As a Bioanalysis Expert you will be part of a team at the forefront of oligonucleotide drug discovery focusing on the biological fate of molecules in preclinical species and humans. You will be an expert in your area, providing significant scientific input on bioanalysis of oligonucleotide drugs and conjugates to project teams. This is a lab-based role where you will provide scientific leadership by developing, perform and deliver high quality bioanalysis of oligonucleotide therapeutics and their metabolites in various matrices. You will drive development of bioanalytical techniques and methodologies in parallel with supporting non-clinical in vitro and in vivo studies with quantitative analysis. In this role, you will get the opportunity to contribute to the discovery of new life-changing medicines for patients and both demonstrate and witness what science can do. Responsibilities include:
Develop and implement quantitative bioanalytical methods for oligonucleotides
Influence study design to define the exposure and kinetics of the drug substances
Plan and report all work to appropriate standards (Good Laboratory Standard, GLS) and keep project teams appraised of findings
Identify new approaches and technologies that would improve our ability to support projects
Drive the science of relevant areas of research
Write manuscripts and publish research together with external/internal collaborators

Essential for the role
PhD or equivalent in relevant subject area, and at least five years’ experience relevant to the position
Background in analytical chemistry, biochemistry or similar relevant subject area.
Advanced technical skills in use of liquid chromatography-mass spectrometry (LC-MS) for analysis of oligonucleotides, including a track record of analysing oligonucleotide-based drugs in a variety of matrices
Technical skills to operate, perform regular maintenance, and elementary trouble shooting of LC-MS/MS instruments
Excellent hands-on skills of sample preparation of biological matrices for quantification of drugs, including method development
Scientific leadership, evidenced by a publication track record
Good communication skills in English, both verbal and in writing
Excellent interpersonal skills and strong ability to engage and collaborate across boundaries with a problem-solving attitude and focus on delivery.

Desirable for the role
Experience from industry environment is a plus, but not mandatory.
Expertise in automation equipment and automated processing would be advantageous

This is an exciting opportunity for a talented oligonucleotide bioanalysis scientist to join a strong team at the forefront of DMPK science, to innovate and support the oligonucleotide portfolio of a major pharmaceutical company that has science at its heart and a tremendously strong pipeline whilst being based in the wonderful city of Gothenburg, Sweden.